{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:31:34Z","timestamp":1788359494243,"version":"build-2803163510"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002713","name":"Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023673","name":"Imam Mohammed Ibn Saud Islamic University Deanship of Scientific Research","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}],"id":[{"id":"10.13039\/501100023673","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vph.2025.107563","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T07:57:30Z","timestamp":1764662250000},"page":"107563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies"],"prefix":"10.1016","volume":"162","author":[{"given":"Mokhtar","family":"Rejili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Sadique","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumna","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faouzi","family":"Haouala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subbulakshmi","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/obr.12551","article-title":"Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation","volume":"18","author":"Bray","year":"2017","journal-title":"Obes. Rev."},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7861\/clinmed.2023-0168","article-title":"Causes of obesity: a review","volume":"23","author":"Masood","year":"2023","journal-title":"Clin. Med."},{"issue":"10481","key":"10.1016\/j.vph.2025.107563_bb0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2025.107563_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2024.112389","article-title":"Kaempferol: paving the path for advanced treatments in aging-related diseases","volume":"188","author":"Hussain","year":"2024","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.vph.2025.107563_bb0025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","article-title":"The epidemiology of obesity: a big picture","volume":"33","author":"Hruby","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vph.2025.107563_bb0030","series-title":"Environmental Factors Implicated in Obesity","first-page":"1171507","author":"Verde","year":"2023"},{"issue":"12","key":"10.1016\/j.vph.2025.107563_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14120833","article-title":"MC-LR aggravates liver lipid metabolism disorders in obese mice fed a high-fat diet via PI3K\/AKT\/mTOR\/SREBP1 signaling pathway","volume":"14","author":"Chu","year":"2022","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0040","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/nyas.12020","article-title":"The genetics of human obesity","volume":"1281","author":"Xia","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.vph.2025.107563_bb0045","article-title":"Pharmacologic treatment of overweight and obesity in adults","volume":"1","author":"Tchang","year":"2024","journal-title":"Endotext"},{"key":"10.1016\/j.vph.2025.107563_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2021.114333","article-title":"Peptide-based system for sensing Pb(2+) and molecular logic computing","volume":"630","author":"Lu","year":"2021","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.vph.2025.107563_bb0055","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s42255-025-01295-w","article-title":"GIPR-Ab\/GLP-1 peptide\u2013antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice","volume":"7","author":"Liu","year":"2025","journal-title":"Nat. Metab."},{"issue":"6","key":"10.1016\/j.vph.2025.107563_bb0060","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s00394-023-03162-4","article-title":"Whey protein hydrolysates improve high-fat-diet-induced obesity by modulating the brain\u2013peripheral axis of GLP-1 through inhibition of DPP-4 function in mice","volume":"62","author":"Rai","year":"2023","journal-title":"Eur. J. Nutr."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0065","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, Meta-analysis, and Meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0070","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-physiol-021113-170404","article-title":"The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on","volume":"76","author":"Manning","year":"2014","journal-title":"Annu. Rev. Physiol."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0031-6997(24)01352-8","article-title":"International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors","volume":"50","author":"Michel","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.vph.2025.107563_bb0080","series-title":"Investigating the Physiological and Pharmacological Effects of the Gut Hormone Peptide YY (PYY)","author":"Alonso","year":"2022"},{"issue":"6","key":"10.1016\/j.vph.2025.107563_bb0085","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3390\/nu16060904","article-title":"Effects of NPY-2 receptor antagonists, Semaglutide, PYY3-36, and Empagliflozin on early MASLD in diet-induced obese rats","volume":"16","author":"Kloock","year":"2024","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0090","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/medicina61030504","article-title":"Role of DPP-4 and NPY family peptides in gastrointestinal symptoms associated with obesity and type 2 diabetes mellitus","volume":"61","author":"Malinauskas","year":"2025","journal-title":"Medicina"},{"issue":"791","key":"10.1016\/j.vph.2025.107563_bb0095","doi-asserted-by":"crossref","first-page":"eadq6392","DOI":"10.1126\/scitranslmed.adq6392","article-title":"Variant screening of PYY3\u201336 leads to potent long-acting PYY analogs with superior Y2 receptor selectivity","volume":"17","author":"\u00d8stergaard","year":"2025","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jgr.2022.03.007","article-title":"Regulation of appetite-related neuropeptides by Panax ginseng: a novel approach for obesity treatment","volume":"46","author":"Phung","year":"2022","journal-title":"J. Ginseng Res."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/metabo15020109","article-title":"Naringenin decreases retroperitoneal adiposity and improves metabolic parameters in a rat model of Western diet-induced obesity","volume":"15","author":"L\u00f3pez-Almada","year":"2025","journal-title":"Metabolites"},{"issue":"9","key":"10.1016\/j.vph.2025.107563_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24091714","article-title":"Revealing drug-target interactions with computational models and algorithms","volume":"24","author":"Zhou","year":"2019","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0115","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.slasd.2022.07.001","article-title":"Screening for positive allosteric modulators of cholecystokinin type 1 receptor potentially useful for management of obesity","volume":"27","author":"Dengler","year":"2022","journal-title":"SLAS Discovery"},{"key":"10.1016\/j.vph.2025.107563_bb0120","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1007\/s10753-025-02289-2","article-title":"Isoorientin ameliorates macrophage Pyroptosis and Atherogenesis by reducing KDM4A levels and promoting SKP1-Cullin1-F-box E3 ligase-mediated NLRP3 ubiquitination","volume":"48","author":"Wang","year":"2025","journal-title":"Inflammation"},{"key":"10.1016\/j.vph.2025.107563_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.717544","article-title":"LEAP-2: an emerging endogenous ghrelin receptor antagonist in the pathophysiology of obesity","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.vph.2025.107563_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155550","article-title":"Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight\/obesity: data from two phase I, randomised, placebo-controlled studies","volume":"143","author":"Bianzano","year":"2023","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0135","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1084\/jem.5.5.527","article-title":"The relation Oe diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands Oe Langerhans","volume":"5","author":"Opie","year":"1901","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0140","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0006-291X(86)90708-4","article-title":"A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas","volume":"140","author":"Westermark","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.vph.2025.107563_bb0145","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.3390\/jcm11082207","article-title":"Mediators of amylin action in metabolic control","volume":"11","author":"Boyle","year":"2022","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.vph.2025.107563_bb0150","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog Pramlintide in obese subjects: a phase 2, Randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2025.107563_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175837","article-title":"Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss","volume":"954","author":"Thors\u00f8 Larsen","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2025.107563_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2022.105965","article-title":"Creating the amylin story","volume":"172","author":"Lutz","year":"2022","journal-title":"Appetite"},{"key":"10.1016\/j.vph.2025.107563_bb0165","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s001250050646","article-title":"Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM","volume":"40","author":"Kong","year":"1997","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-0495(96)90192-4","article-title":"Preliminary report dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7\u201336)NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake","volume":"45","author":"Young","year":"1996","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0175","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/BF01925572","article-title":"Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat","volume":"52","author":"clementi","year":"1996","journal-title":"Experientia"},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0180","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1046\/j.1365-2362.2003.01142.x","article-title":"Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects","volume":"33","author":"Ludvik","year":"2003","journal-title":"Eur. J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0185","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2009-2133","article-title":"Do the actions of glucagon-like Peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?","volume":"95","author":"Asmar","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0190","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0195","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/all.15111","article-title":"Regulatory roles of three miRNAs on allergen mRNA expression in Tyrophagus putrescentiae","volume":"77","author":"Zhou","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.vph.2025.107563_bb0200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.physbeh.2014.01.013","article-title":"Amylin activates distributed CNS nuclei to control energy balance","volume":"136","author":"Mietlicki-Baase","year":"2014","journal-title":"Physiol. Behav."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0205","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000107579","article-title":"Diet-derived nutrients modulate the effects of amylin on c-Fos expression in the area postrema and on food intake","volume":"86","author":"Michel","year":"2007","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.vph.2025.107563_bb0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.physbeh.2013.02.006","article-title":"Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli","volume":"112-113","author":"Z\u00fcger","year":"2013","journal-title":"Physiol. Behav."},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0215","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.ijo.0801664","article-title":"The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema\/nucleus of the solitary tract (AP\/NTS) lesioned rats","volume":"25","author":"Lutz","year":"2001","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.vph.2025.107563_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101240","article-title":"A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing","volume":"53","author":"Dowsett","year":"2021","journal-title":"Mol. Metab."},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0225","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1210\/en.2012-2172","article-title":"Amylin acts in the central nervous system to increase sympathetic nerve activity","volume":"154","author":"Fernandes-Santos","year":"2013","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.vph.2025.107563_bb0230","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1210\/en.2006-0393","article-title":"Antiobesity effects of the \u03b2-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression","volume":"147","author":"Roth","year":"2006","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0240","article-title":"Calcitonin receptors in GtoPdb v. 2023.1","volume":"2023","author":"Garelja","year":"2023","journal-title":"IUPHAR\/BPS Guide Pharmacol. CITE"},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0245","first-page":"3778","article-title":"Metformin induces M2 polarization via AMPK\/PGC-1\u03b1\/PPAR-\u03b3 pathway to improve peripheral nerve regeneration","volume":"15","author":"Zhou","year":"2023","journal-title":"Am. J. Transl. Res."},{"issue":"6587","key":"10.1016\/j.vph.2025.107563_bb0250","doi-asserted-by":"crossref","first-page":"eabm9609","DOI":"10.1126\/science.abm9609","article-title":"A structural basis for amylin receptor phenotype","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vph.2025.107563_bb0255","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neures.2024.10.001","article-title":"Ventral tegmental area amylin \/ calcitonin receptor signaling suppresses feeding and weight gain in female rats","volume":"212","author":"Gustafson","year":"2025","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.vph.2025.107563_bb0260","series-title":"Amylin Receptor Subunit Interactions Are Modulated by Agonists and Determine Signaling","author":"Gostynska","year":"2024"},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0265","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1111\/ejn.12672","article-title":"The role of the area postrema in the anorectic effects of amylin and salmon calcitonin: behavioral and neuronal phenotyping","volume":"40","author":"Braegger","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.vph.2025.107563_bb0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-4939-7860-1_5","article-title":"Reporter-based BRET sensors for measuring biological functions in vivo","volume":"1790","author":"Rathod","year":"2018","journal-title":"Methods. Mol. Biol. (Clifton, N.J.)"},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0275","doi-asserted-by":"crossref","first-page":"R697","DOI":"10.1152\/ajpregu.00338.2020","article-title":"Amylin antibodies frequently display cross-reactivity with CGRP: characterization of eight amylin antibodies","volume":"320","author":"Rees","year":"2021","journal-title":"Am. J. Physiol. Regul. Intgr. Comp. Physiol."},{"issue":"17","key":"10.1016\/j.vph.2025.107563_bb0280","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1007\/s00018-015-1904-4","article-title":"Molecular and cellular mechanisms that initiate pain and itch","volume":"72","author":"Luo","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ilar.47.3.225","article-title":"Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes","volume":"47","author":"Matveyenko","year":"2006","journal-title":"ILAR J."},{"issue":"6","key":"10.1016\/j.vph.2025.107563_bb0290","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ajpath.2011.02.036","article-title":"\u0392-Cell loss and \u03b2-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition","volume":"178","author":"Jurgens","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0295","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/advances\/nmy084","article-title":"Glutamine metabolism in macrophages: a novel target for obesity\/type 2 diabetes","volume":"10","author":"Ren","year":"2019","journal-title":"Adv. Nutr. (Bethesda, Md.)"},{"issue":"6","key":"10.1016\/j.vph.2025.107563_bb0300","doi-asserted-by":"crossref","first-page":"R1032","DOI":"10.1152\/ajpregu.00326.2016","article-title":"Early postnatal amylin treatment enhances hypothalamic leptin signaling and neural development in the selectively bred diet-induced obese rat","volume":"311","author":"Johnson","year":"2016","journal-title":"Am. J. Physiol. Regul. Intgr. Comp. Physiol."},{"issue":"1_suppl","key":"10.1016\/j.vph.2025.107563_bb0305","doi-asserted-by":"crossref","first-page":"47S","DOI":"10.1177\/0145721715607642","article-title":"Role of amylin in type 1 and type 2 diabetes","volume":"41","author":"Hieronymus","year":"2015","journal-title":"Diabetes Educ."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0310","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1210\/en.2009-0546","article-title":"Mechanisms of amylin\/leptin synergy in rodent models","volume":"151","author":"Turek","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.vph.2025.107563_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121268","article-title":"Hypothalamic anorexigenic signaling pathways (leptin, amylin, and proopiomelanocortin) are semaglutide (GLP-1 analog) targets in obesity control in mice","volume":"313","author":"Martins","year":"2023","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.vph.2025.107563_bb0320","doi-asserted-by":"crossref","first-page":"E924","DOI":"10.1152\/ajpendo.00198.2011","article-title":"Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice","volume":"302","author":"Kusakabe","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0325","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bbrc.2019.01.023","article-title":"Alpha-glucosidase inhibitor 1-Deoxynojirimycin promotes beige remodeling of 3T3-L1 preadipocytes via activating AMPK","volume":"509","author":"Li","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.vph.2025.107563_bb0330","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1210\/en.2007-0898","article-title":"Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity","volume":"148","author":"Roth","year":"2007","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0335","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0196-9781(97)00124-1","article-title":"Different influence of CGRP(8-37), an amylin and CGRP antagonist, on the anorectic effects of cholecystokinin and Bombesin in diabetic and Normal rats","volume":"18","author":"Lutz","year":"1997","journal-title":"Peptides"},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0340","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3149","article-title":"Melanocortin 4 receptor\u2013mediated effects of amylin on thermogenesis and regulation of food intake","volume":"35","author":"Li","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0345","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1463-1326.2012.01570.x","article-title":"Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents","volume":"14","author":"Roth","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.vph.2025.107563_bb0350","doi-asserted-by":"crossref","first-page":"1645587","DOI":"10.3389\/fphar.2025.1645587","article-title":"Targeting adipocyte differentiation with CRT0066101: activation of AMPK signaling in 3T3-L1 cells","volume":"16","author":"Luo","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.vph.2025.107563_bb0355","doi-asserted-by":"crossref","first-page":"R1697","DOI":"10.1152\/ajpregu.2001.280.6.R1697","article-title":"Dopamine D2 receptors mediate amylin's acute satiety effect","volume":"280","author":"Lutz","year":"2001","journal-title":"Am. J. Physiol. Regul. Intgr. Comp. Physiol."},{"issue":"10","key":"10.1016\/j.vph.2025.107563_bb0360","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.biopsych.2023.07.011","article-title":"Amylin modulates a ventral tegmental area\u2013to\u2013medial prefrontal cortex circuit to suppress food intake and impulsive food-directed behavior","volume":"95","author":"Geisler","year":"2024","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.vph.2025.107563_bb0365","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0133-24.2024","article-title":"Ventral tegmental area amylin receptor activation differentially modulates mesolimbic dopamine signaling in response to fat versus sugar","volume":"11","author":"Bhimani","year":"2024","journal-title":"eNeuro"},{"issue":"13","key":"10.1016\/j.vph.2025.107563_bb0370","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/npp.2014.153","article-title":"Amylin receptor signaling in the nucleus Accumbens negatively modulates \u03bc-opioid-driven feeding","volume":"39","author":"Baisley","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.vph.2025.107563_bb0375","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/protein\/gzp029","article-title":"Solution state structures of human pancreatic amylin and pramlintide","volume":"22","author":"Cort","year":"2009","journal-title":"Protein Eng. Des. Sel."},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4952","article-title":"Unraveling the underlying mechanisms of reduced amyloidogenic properties in human calcitonin via double mutations","volume":"33","author":"Chang","year":"2024","journal-title":"Protein Sci."},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0385","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-Semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120479","article-title":"Differential effect of amylin on endothelial-dependent vasodilation in mesenteric arteries from control and insulin resistant rats","volume":"10","author":"El Assar","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107733","article-title":"Diabetic gastroparesis: an overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists","volume":"35","author":"Petri","year":"2021","journal-title":"J. Diabetes Complicat."},{"issue":"8","key":"10.1016\/j.vph.2025.107563_bb0400","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0405","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ijo.2009.238","article-title":"Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight","volume":"34","author":"Mack","year":"2010","journal-title":"Int. J. Obes. (Lond) (2005)"},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0410","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1124\/jpet.121.000567","article-title":"AM833 is a novel agonist of calcitonin family G protein-coupled receptors: pharmacological comparison with six selective and nonselective agonists","volume":"377","author":"Fletcher","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0415","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1124\/mol.106.024257","article-title":"A critical role for the short intracellular C terminus in receptor activity-modifying protein function","volume":"70","author":"Udawela","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"12","key":"10.1016\/j.vph.2025.107563_bb0420","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1463-1326.2011.01465.x","article-title":"Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide","volume":"13","author":"Mack","year":"2011","journal-title":"Diabetes Obes. Metab."},{"issue":"15","key":"10.1016\/j.vph.2025.107563_bb0425","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of Cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0430","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s11739-023-03237-4","article-title":"Pharmacotherapy for chronic obesity management: a look into the future","volume":"18","author":"Abdel-Malek","year":"2023","journal-title":"Intern. Emerg. Med."},{"issue":"10317","key":"10.1016\/j.vph.2025.107563_bb0435","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"10286","key":"10.1016\/j.vph.2025.107563_bb0440","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0445","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14656566.2024.2311731","article-title":"Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?","volume":"25","author":"Le Roux","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.vph.2025.107563_bb0450","article-title":"Novo Nordisk shares early findings for novel oral antiobesity agent","volume":"p1","author":"Halsey","year":"2024","journal-title":"Patient Care"},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0455","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/17446651.2023.2209176","article-title":"Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction","volume":"18","author":"Maki","year":"2023","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2025.107563_bb0460","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000940","article-title":"Advancing diabetes management and glycemic control while exploring CagriSema\u2019s impact on obesity management","author":"Hadid","year":"2025","journal-title":"Cardiol. Rev."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0465","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00121.2014","article-title":"A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats","volume":"307","author":"Andreassen","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0470","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1124\/jpet.119.257576","article-title":"The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy","volume":"370","author":"Larsen","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0475","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/jpet.119.263400","article-title":"Dose frequency optimization of the dual amylin and calcitonin receptor agonist KBP-088: long-lasting improvement in food preference and body weight loss","volume":"373","author":"Larsen","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0480","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.vph.2025.107563_bb0485","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1111\/bcp.14921","article-title":"Safety, tolerability and pharmacokinetic characterisation of DACRA KBP-042 in healthy male subjects","volume":"87","author":"Henriksen","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2025.107563_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101282","article-title":"KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats","volume":"53","author":"Andreassen","year":"2021","journal-title":"Mol. Metab."},{"issue":"10","key":"10.1016\/j.vph.2025.107563_bb0495","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102365","article-title":"The impact of exposure profile on the efficacy of dual amylin and calcitonin receptor agonist therapy","volume":"10","author":"Sonne","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.vph.2025.107563_bb0500","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1530\/EJE-21-1261","article-title":"THERAPY OF ENDOCRINE DISEASE: amylin and calcitonin - physiology and pharmacology","volume":"186","author":"Mathiesen","year":"2022","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0505","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/bcpt.13427","article-title":"Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases","volume":"127","author":"Zakariassen","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0510","doi-asserted-by":"crossref","first-page":"R250","DOI":"10.1152\/ajpregu.00337.2020","article-title":"The long-acting amylin\/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats","volume":"321","author":"Stein","year":"2021","journal-title":"Am. J. Physiol. Regul. Intgr. Comp. Physiol."},{"key":"10.1016\/j.vph.2025.107563_bb0515","series-title":"Safety, Tolerability, and Clinical Effects of Petrelintide (ZP8396), A Long-Acting Amylin Analog","first-page":"38","author":"Olsen","year":"2024"},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0520","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1243","article-title":"Novel Pharmaceuticals in Appetite Regulation: exploring emerging gut peptides and their pharmacological prospects","volume":"12","author":"Rubini\u0107","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"issue":"Supplement_1","key":"10.1016\/j.vph.2025.107563_bb0525","doi-asserted-by":"crossref","DOI":"10.2337\/db23-92-LB","article-title":"92-LB: safety, tolerability, and clinical effects of ZP8396, a novel long-acting amylin analog\u2014a single ascending dose trial","volume":"72","author":"Olsen","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.vph.2025.107563_bb0530","first-page":"84","article-title":"Safety, tolerability, and clinical effects of ZP8396, an amylin analog: multiple ascending dose trial","volume":"31","author":"Hovelmann","year":"2023","journal-title":"Obesity"},{"issue":"Supplement_1","key":"10.1016\/j.vph.2025.107563_bb0535","doi-asserted-by":"crossref","DOI":"10.2337\/db24-1668-P","article-title":"1668-P: novel once-weekly amylin analog petrelintide (ZP8396) is well tolerated with improved GI tolerability after multiple dosing","volume":"73","author":"Griffin","year":"2024","journal-title":"Diabetes"},{"issue":"15","key":"10.1016\/j.vph.2025.107563_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158202","article-title":"Molecular mechanisms behind obesity and their potential exploitation in current and future therapy","volume":"25","author":"Nicze","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/biom12070996","article-title":"Amylin and secretases in the pathology and treatment of Alzheimer\u2019s disease","volume":"12","author":"Singh","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.vph.2025.107563_bb0550","first-page":"1","article-title":"Amylin analogs for the treatment of obesity without diabetes: present and future","author":"Panou","year":"2024","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0555","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CRD.0000000000000513","article-title":"Cagrilintide: a long-acting amylin analog for the treatment of obesity","volume":"32","author":"D\u2019Ascanio","year":"2024","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.vph.2025.107563_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171203","article-title":"Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy","volume":"177","author":"Sun","year":"2024","journal-title":"Peptides"},{"issue":"9","key":"10.1016\/j.vph.2025.107563_bb0565","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/phar.4607","article-title":"Incretin hormone agonists: current and emerging pharmacotherapy for obesity management","volume":"44","author":"Alhomoud","year":"2024","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0570","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eprac.2023.12.010","article-title":"A review of incretin therapies approved and in late-stage development for overweight and obesity management","volume":"30","author":"Chetty","year":"2024","journal-title":"Endocr. Pract."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0575","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3803\/EnM.2024.1940","article-title":"Glucagon-like Peptide-1 based therapies: a new horizon in obesity management","volume":"39","author":"Son","year":"2024","journal-title":"Endocrinol. Metab. (Seoul, Korea)"},{"issue":"9","key":"10.1016\/j.vph.2025.107563_bb0580","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s11886-024-02097-4","article-title":"Curbing the obesity epidemic: should GLP-1 receptor agonists be the standard of care for obesity?","volume":"26","author":"Kaplan","year":"2024","journal-title":"Curr. Cardiol. Rep."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0585","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/jpet.123.001679","article-title":"Pramlintide an adjunct to insulin therapy: challenges and recent progress in delivery","volume":"388","author":"Kommera","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0590","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clinthera.2007.04.005","article-title":"Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus","volume":"29","author":"Singh-Franco","year":"2007","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0595","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpeds.2009.03.012","article-title":"Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study","volume":"155","author":"Chase","year":"2009","journal-title":"J. Pediatr."},{"issue":"13","key":"10.1016\/j.vph.2025.107563_bb0600","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2165\/00003495-200464130-00003","article-title":"Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data","volume":"64","author":"Kruger","year":"2004","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.vph.2025.107563_bb0605","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/ajhp\/zxz179","article-title":"Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus","volume":"76","author":"Guyton","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0610","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031517","article-title":"Amylin, another important neuroendocrine hormone for the treatment of diabesity","volume":"25","author":"Er\u017een","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.vph.2025.107563_bb0615","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2174\/1389203720666190328111833","article-title":"Human amylin: from pathology to physiology and pharmacology","volume":"20","author":"Ling","year":"2019","journal-title":"Curr. Protein Pept. Sci."},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0620","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1210\/jc.2006-1980","article-title":"Amylin and hypertension: association of an amylin -G132A gene mutation and hypertension in humans and amylin-induced endothelium dysfunction in rats","volume":"92","author":"Novials","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.vph.2025.107563_bb0625","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000057400","article-title":"Interaction of the renal amylin and renin-angiotensin systems in animal models of diabetes and hypertension","volume":"24","author":"Wookey","year":"1998","journal-title":"Miner. Electrolyte Metab."},{"issue":"1\u20132","key":"10.1016\/j.vph.2025.107563_bb0630","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.regpep.2005.04.001","article-title":"Amylin induces natriuresis by a central angiotensin-dependent mechanism","volume":"130","author":"Mathai","year":"2005","journal-title":"Regul. Pept."},{"issue":"2\u20133","key":"10.1016\/j.vph.2025.107563_bb0635","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1615\/CritRevNeurobiol.v11.i2-3.40","article-title":"Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily","volume":"11","author":"Wimalawansa","year":"1997","journal-title":"Crit. Rev. Neurobiol."},{"issue":"10403","key":"10.1016\/j.vph.2025.107563_bb0640","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2025.107563_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol. Metab."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0650","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","article-title":"Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity","volume":"26","author":"Jepsen","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0655","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14656566.2024.2356254","article-title":"Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?","volume":"25","author":"Gogineni","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0660","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson","year":"2025","journal-title":"Int. J. Obes."},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0665","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4103\/ijem.ijem_45_24","article-title":"Efficacy and safety of Cagrilintide alone and in combination with Semaglutide (Cagrisema) as anti-obesity medications: a systematic review and meta-analysis","volume":"28","author":"Dutta","year":"2024","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2025.107563_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter? - comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0675","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/17446651.2024.2347258","article-title":"Advancements in the management of obesity: a review of current evidence and emerging therapies","volume":"19","author":"Abdalla Ahmed","year":"2024","journal-title":"Expert. Rev. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0680","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.vph.2025.107563_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of type 2 diabetes: an update and future directions","volume":"137","author":"DeMarsilis","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.vph.2025.107563_bb0690","article-title":"The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats","volume":"37","author":"Aran\u00e4s","year":"2024","journal-title":"Acta Neuropsychiatr."},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0695","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/hep.32381","article-title":"Discovery of an insulin-induced gene binding compound that ameliorates nonalcoholic steatohepatitis by inhibiting sterol regulatory element-binding protein-mediated lipogenesis","volume":"76","author":"Jiang","year":"2022","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0700","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4103\/ijem.ijem_442_23","article-title":"Approved and emerging hormone-based anti-obesity medications: a review article","volume":"28","author":"Sidrak","year":"2024","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2025.107563_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116150","article-title":"Efficacy and safety of GLP-1RAs for people with obesity: a systematic review based on RCT and Bayesian network meta-analysis","volume":"171","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0710","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","article-title":"The weight-loss effect of GLP-1RAs glucagon-like Peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with Meta-analysis and trial sequential analysis of randomized controlled trials","volume":"118","author":"Liu","year":"2023","journal-title":"Am. J. Clin. Nutr."},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0715","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0720","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7326\/M15-1432","article-title":"Benefits and harms of once-weekly glucagon-like Peptide-1 receptor agonist treatments: a systematic review and network Meta-analysis","volume":"164","author":"Zaccardi","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0725","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"7\u20138","key":"10.1016\/j.vph.2025.107563_bb0730","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1345\/aph.1Q024","article-title":"Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"45","author":"Pinelli","year":"2011","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0735","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13543784.2025.2472408","article-title":"The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines","volume":"34","author":"Madsbad","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0740","doi-asserted-by":"crossref","first-page":"35","DOI":"10.17925\/EE.2022.18.1.35","article-title":"Once-weekly 2.4 mg semaglutide for weight management in obesity: a game changer?","volume":"18","author":"Colin","year":"2022","journal-title":"TouchREVIEWS Endocrinol."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0745","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/17512433.2022.2070473","article-title":"Pharmacological profile of once-weekly injectable semaglutide for chronic weight management","volume":"15","author":"Lau","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.vph.2025.107563_bb0750","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/13543784.2017.1360274","article-title":"Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes","volume":"26","author":"Tan","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.vph.2025.107563_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110191","article-title":"Development of the novel amylin and calcitonin receptor activators by peptide mutagenesis","volume":"762","author":"Lee","year":"2024","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.vph.2025.107563_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171314","article-title":"Modulation of amylin and calcitonin receptor activation by hybrid peptides","volume":"182","author":"Lee","year":"2024","journal-title":"Peptides"},{"issue":"3\u20134","key":"10.1016\/j.vph.2025.107563_bb0765","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/10606820213683","article-title":"Receptors for calcitonin gene-related peptide, adrenomedullin, and amylin: the contributions of novel receptor-activity-modifying proteins","volume":"8","author":"Born","year":"2002","journal-title":"Recept. Channels"},{"issue":"31","key":"10.1016\/j.vph.2025.107563_bb0770","doi-asserted-by":"crossref","first-page":"16416","DOI":"10.1074\/jbc.A115.713628","article-title":"Calcitonin and amylin receptor peptide interaction mechanisms. Insights into peptide-binding modes and allosteric modulation of the calcitonin receptor by receptor activity-modifying proteins","volume":"291","author":"Lee","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.vph.2025.107563_bb0775","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1074\/jbc.RA118.001975","article-title":"Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells","volume":"293","author":"Wan","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0780","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1021\/acs.bioconjchem.6b00112","article-title":"NanoLuc: a small luciferase is brightening up the field of bioluminescence","volume":"27","author":"England","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0785","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/molpharm.123.000865","article-title":"Development of a novel assay for direct assessment of selective amylin receptor activation reveals novel differences in behavior of selective and nonselective peptide agonists","volume":"105","author":"Keov","year":"2024","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0790","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s10194-021-01295-7","article-title":"Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy","volume":"22","author":"Scuteri","year":"2021","journal-title":"J. Headache Pain"},{"issue":"7536","key":"10.1016\/j.vph.2025.107563_bb0795","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nature13910","article-title":"IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo","volume":"517","author":"Venkatanarayan","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0800","first-page":"117","article-title":"Calcitonin and calcitonin receptors","volume":"4","author":"Masi","year":"2007","journal-title":"Clin. Cases Mineral Bone Metab."},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0805","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41594-020-0442-4","article-title":"Cryo-EM structure of islet amyloid polypeptide fibrils reveals similarities with amyloid-\u03b2 fibrils","volume":"27","author":"R\u00f6der","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.vph.2025.107563_bb0810","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/164_2021_560","article-title":"Drugs for treating obesity","volume":"274","author":"Ryan","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"issue":"7","key":"10.1016\/j.vph.2025.107563_bb0815","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bph.12129","article-title":"CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?","volume":"170","author":"Walker","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0820","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1038\/s41467-025-58680-y","article-title":"Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors","volume":"16","author":"Cao","year":"2025","journal-title":"Nat. Commun."},{"issue":"10403","key":"10.1016\/j.vph.2025.107563_bb0825","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(23)01291-6","article-title":"CagriSema and the link between obesity and type 2 diabetes","volume":"402","author":"Apovian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2025.107563_bb0830","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pcad.2024.01.003","article-title":"Update on obesity, the obesity paradox, and obesity management in heart failure","volume":"82","author":"Alebna","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0835","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-023-01530-2","article-title":"Polyagonists in type 2 diabetes management","volume":"24","author":"Dissanayake","year":"2024","journal-title":"Curr. Diab. Rep."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0840","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MED.0000000000000716","article-title":"Long-acting amylin analogues for the management of obesity","volume":"29","author":"Mathiesen","year":"2022","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0845","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00417-023-06236-5","article-title":"Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review","volume":"262","author":"Ntentakis","year":"2024","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0850","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: a systematic review","volume":"77","author":"Kokkorakis","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.vph.2025.107563_bb0855","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s11095-022-03302-1","article-title":"Therapeutic potential of Semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review","volume":"39","author":"Mahapatra","year":"2022","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.vph.2025.107563_bb0860","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bph.16278","article-title":"Newer pharmacological interventions directed at gut hormones for obesity","volume":"181","author":"Camilleri","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.vph.2025.107563_bb0865","first-page":"472","article-title":"Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists","volume":"27","author":"Beauregard","year":"2024","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0870","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13679-018-0300-4","article-title":"Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon","volume":"7","author":"Srivastava","year":"2018","journal-title":"Curr. Obes. Rep."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0875","doi-asserted-by":"crossref","DOI":"10.1002\/osp4.756","article-title":"Healthcare professionals\u2019 perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists","volume":"10","author":"Garvey","year":"2024","journal-title":"Obes. Sci. Pract."},{"key":"10.1016\/j.vph.2025.107563_bb0880","doi-asserted-by":"crossref","first-page":"6134362","DOI":"10.1155\/2020\/6134362","article-title":"Epidemiology, predisposing factors, biomarkers, and prevention mechanism of obesity: a systematic review","volume":"2020","author":"Endalifer","year":"2020","journal-title":"J. Obes."},{"key":"10.1016\/j.vph.2025.107563_bb0885","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.metabol.2018.12.006","article-title":"Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine","volume":"92","author":"Nimptsch","year":"2019","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.vph.2025.107563_bb0890","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.7150\/ijbs.78535","article-title":"The emerging role of super-enhancers as therapeutic targets in the digestive system tumors","volume":"19","author":"Li","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0895","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/0884533613516168","article-title":"Clinical biomarkers in metabolic syndrome","volume":"29","author":"Barazzoni","year":"2014","journal-title":"Nutr. Clin. Pract."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0900","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc. Med."},{"issue":"sup1","key":"10.1016\/j.vph.2025.107563_bb0905","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/00325481.2022.2147325","article-title":"Cardiometabolic risk factors efficacy of semaglutide in the STEP program","volume":"134","author":"Amaro","year":"2022","journal-title":"Postgrad. Med."},{"issue":"1","key":"10.1016\/j.vph.2025.107563_bb0910","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jim-2021-001952","article-title":"Wegovy (semaglutide): a new weight loss drug for chronic weight management","volume":"70","author":"Singh","year":"2022","journal-title":"J. Investig. Med."},{"issue":"3","key":"10.1016\/j.vph.2025.107563_bb0915","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0030-1262790","article-title":"Effects of exercise on the levels of peptide YY and ghrelin","volume":"119","author":"Li","year":"2011","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"17","key":"10.1016\/j.vph.2025.107563_bb0920","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.vph.2025.107563_bb0925","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/14656566.2023.2208746","article-title":"Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes","volume":"24","author":"Brodosi","year":"2023","journal-title":"Expert. Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0930","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41401-021-00836-9","article-title":"GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis","volume":"43","author":"Chen","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.vph.2025.107563_bb0935","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221146371","volume":"27","author":"Muzurovi\u0107","year":"2022","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0940","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1570161117666190405164313","article-title":"Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block","volume":"18","author":"Athyros","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2025.107563_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114969","article-title":"Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss","volume":"164","author":"Larsen","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.vph.2025.107563_bb0950","doi-asserted-by":"crossref","first-page":"E145","DOI":"10.1152\/ajpendo.00092.2024","article-title":"The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes","volume":"327","author":"Larsen","year":"2024","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.vph.2025.107563_bb0955","doi-asserted-by":"crossref","first-page":"E529","DOI":"10.1152\/ajpendo.00245.2023","article-title":"Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats","volume":"325","author":"Melander","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.vph.2025.107563_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101109","article-title":"Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases","volume":"46","author":"Sonne","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.vph.2025.107563_bb0965","article-title":"Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat","volume":"11","author":"Mathiesen","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912500103X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153718912500103X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:17:24Z","timestamp":1781335044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153718912500103X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":193,"alternative-id":["S153718912500103X"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2025.107563","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2025.107563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107563"}}